Patient with parasitic infection which affects the liver, lungs, and peritoneum (hydatid disease) should be assessed properly before starting the Tanzol therapy.
Bone Marrow Suppression
Patients with liver disease are at an increased risk of bone marrow suppression while using Tanzol. Such patients may have an increased risk of fatality due to the reduced number of blood granulocytes (Granulocytopenia). Tanzol should be discontinued if there is a significant decrease in blood cell count.
Pregnant women and women who want to conceive are at an increased risk when using this medicine. Use of this medicine in pregnant women may cause harm to the fetus. Use effective birth control measures for the duration of Tanzol treatment, and it should be continued for one month even after the end of therapy. Discontinue the use of Tanzol if a patient becomes pregnant.
Patients with tapeworm infection that affects the brain, muscles and body tissues (neurocysticercosis) are at an increased risk when using Tanzol. These patients may develop seizures
and increased pressure within the brain. Such patients should take steroid
and anticonvulsant therapy to prevent brain related symptoms.
Tapeworm Infection of the Eye
Patients with the tumor
in the eyes (retinal lesions) are at an increased risk. Tanzol kills the parasite and can cause retinal damage. Proper eye check-up should be done before the start of the Tanzol therapy.
Patients with increased liver enzymes are at an increased risk when using this medicine. Such patients are at an increased risk of liver damage and bone marrow suppression. Discontinue the use of Tanzol if liver enzymes get significantly increased or if there is a decrease in blood cell count.